Clinical Research Center for Innovative Treatments

At Providence, our staff strives to bring you the latest and greatest medical advancements in the comfort of our community hospital. In order to find and bring to you the newest advancements in the medical field, Providence Hospital created the Clinical Research Center.

Clinical Trials Provide Medical Breakthroughs

The Clinical Research Center (CRC), established in January 2006, supports the hospital’s mission of service to the community through the establishment and growth of our Clinical Trials Program. The CRC provides patients and physicians with the opportunity to participate in some of the latest breakthroughs in medicine, and allows physicians to pursue clinical research in a true community hospital. Partnered with distinguished members of the Medical Staff, the CRC brings a diverse group of clinical studies that would otherwise be unavailable to the Providence community.


A Phase 2, multicenter, randomized, double-blind, comparative study of the safety and efficacy of 2 doses of tigecycline versus Imipenem/Cilastin for the treatment of subjects with hospital-acquired pneumonia

Principal Investigator: Jose Bordon, MD
Contact Person: Felicia Elvis
Contact Number: (202) 448-4049

Linezolid in the Treatment of Subjects with Nosocomial Pneumonia Proven to be Due to Methicillin-Resistant Staphylococcus Aureus

Prinicipal Investigator: Muhammad Shibli, MD
Contact Person: Augustine Nwabueze
Contact Number: (202) 448-4054

Chronic Kidney Disease

A Phase III, Randomized, Double-blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progression in Patients with Moderate to Severe Chronic Kidney Disease

Principal Investigator: Anthony Bivins, MD
Contact Person: Augustine Nwabueze
Contact Number: (202) 448-4054


A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy.

Principal Investigator: Harminder Sethi, MD
Contact Person: Felicia Elvis
Contact Number: (202) 448-4049


A multicenter, randomized double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo, in patients with type 2 diabetes mellitus inadequately controlled with metformin plus pioglitazone

Principal Investigator: Ana Ibrado, MD, PhD
Contact Person: Felicia Elvis
Contact Number: (202) 448-4049

Contact the Clinical Research Center

For more information about the Clinical Research Center or studies we are currently conducting, please call (202) 448-4048.

Main hospital Phone: (202) 269 7000

Providence Hospital, 1150 Varnum Street, N.E. Washington, DC 20017 2180